Table 3.
Dual effects of inflammatory markers and FGF23 on all-cause mortality
| Hazard Ratio (95% Confidence Interval) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Unadjusted | P | Model A | P | Model B | P | Model C | P | |
| IL-6 and FGF23 | ||||||||
| Separate Cox proportional hazards models of each individual exposure (from Table 2) | ||||||||
| per 1 SD of lnIL-6 | 1.52 (1.43–1.61) | < .0001 | 1.38 (1.28–1.49) | < .0001 | 1.38 (1.28–1.48) | < .0001 | 1.35 (1.25–1.46) | < .0001 |
| per 1 SD of lnFGF23 | 1.64 (1.53–1.76) | < .0001 | 1.53 (1.40–1.67) | < .0001 | 1.51 (1.38–1.65) | < .0001 | 1.45 (1.32–1.60) | < .0001 |
| Single Cox proportional hazards model that includes both IL-6 and FGF23 | ||||||||
| per 1 SD of lnIL-6 | 1.39 (1.30–1.48) | < .0001 | 1.30 (1.20–1.41) | < .0001 | 1.30 (1.20–1.41) | < .0001 | 1.29 (1.18–1.40) | < .0001 |
| per 1 SD of lnFGF23 | 1.47 (1.36–1.58) | < .0001 | 1.42 (1.30–1.55) | < .0001 | 1.40 (1.28–1.54) | < .0001 | 1.36 (1.23–1.50) | < .0001 |
| CRP and FGF23 | ||||||||
| Separate Cox proportional hazards models of each individual exposure (from Table 2) | ||||||||
| per 1 SD of lnCRP | 1.39 (1.27–1.51) | < .0001 | 1.31 (1.19–1.43) | < .0001 | 1.28 (1.17–1.40) | < .0001 | 1.28 (1.16–1.40) | < .0001 |
| per 1 SD of lnFGF23 | 1.64 (1.53–1.76) | < .0001 | 1.53 (1.40–1.67) | < .0001 | 1.51 (1.38–1.65) | < .0001 | 1.45 (1.32–1.60) | < .0001 |
| Single Cox proportional hazards model that includes both CRP and FGF23 | ||||||||
| per 1 SD of lnCRP | 1.26 (1.15–1.37) | < .0001 | 1.23 (1.13–1.35) | < .0001 | 1.22 (1.11–1.33) | < .0001 | 1.22 (1.11–1.33) | < .0001 |
| per 1 SD of lnFGF23 | 1.58 (1.46–1.70) | < .0001 | 1.48 (1.35–1.62) | < .0001 | 1.46 (1.34–1.60) | < .0001 | 1.41 (1.28–1.55) | < .0001 |
Model A: Stratified by site and adjusted for age, sex, race, ethnicity, body mass index, diabetes, smoking status, history of cardiovascular disease, systolic blood pressure, estimated glomerular filtration rate, urine albumin-to-creatinine ratio categories, serum albumin, hemoglobin, low-density lipoprotein
Model B: Model A plus use of use of aspirin, beta blockers, statins, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, active vitamin D, nutritional vitamin D, phosphate binders, and steroids.
Model C: Model B plus serum calcium, phosphate and parathyroid hormone.
IL-6, interleukin-6; CRP, high-sensitivity C-reactive protein; SD, standard deviation